Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Deep Brain Stimulation | 8 | 2017 | 36 | 1.510 |
Why?
|
| Electrodes, Implanted | 3 | 2017 | 20 | 0.520 |
Why?
|
| Parkinson Disease | 12 | 2013 | 595 | 0.500 |
Why?
|
| Anterior Thalamic Nuclei | 2 | 2010 | 3 | 0.360 |
Why?
|
| Epilepsy | 2 | 2010 | 58 | 0.340 |
Why?
|
| Brain | 5 | 2017 | 1241 | 0.330 |
Why?
|
| Ventral Thalamic Nuclei | 2 | 2017 | 2 | 0.320 |
Why?
|
| Genetic Therapy | 6 | 2014 | 83 | 0.320 |
Why?
|
| Dentate Gyrus | 1 | 2009 | 5 | 0.310 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2009 | 21 | 0.310 |
Why?
|
| Essential Tremor | 1 | 2008 | 3 | 0.290 |
Why?
|
| Neurons | 3 | 2009 | 273 | 0.290 |
Why?
|
| Hypothalamic Area, Lateral | 1 | 2007 | 2 | 0.270 |
Why?
|
| Dependovirus | 3 | 2014 | 38 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 875 | 0.240 |
Why?
|
| Postoperative Complications | 2 | 2009 | 812 | 0.240 |
Why?
|
| Obesity | 1 | 2007 | 288 | 0.220 |
Why?
|
| Neurturin | 3 | 2010 | 22 | 0.210 |
Why?
|
| Stereotaxic Techniques | 4 | 2017 | 14 | 0.210 |
Why?
|
| Adrenal Medulla | 4 | 1997 | 7 | 0.200 |
Why?
|
| Immunohistochemistry | 5 | 2014 | 338 | 0.190 |
Why?
|
| Genetic Vectors | 4 | 2014 | 55 | 0.170 |
Why?
|
| Male | 15 | 2017 | 12659 | 0.170 |
Why?
|
| Transplantation, Heterotopic | 3 | 1997 | 7 | 0.160 |
Why?
|
| Caudate Nucleus | 3 | 1997 | 11 | 0.160 |
Why?
|
| Nerve Growth Factor | 2 | 2014 | 41 | 0.160 |
Why?
|
| Putamen | 2 | 2010 | 19 | 0.150 |
Why?
|
| Humans | 19 | 2017 | 23187 | 0.150 |
Why?
|
| Postoperative Period | 3 | 2017 | 238 | 0.140 |
Why?
|
| Middle Aged | 10 | 2017 | 7981 | 0.140 |
Why?
|
| Peripheral Nerves | 1 | 1997 | 17 | 0.130 |
Why?
|
| Follow-Up Studies | 7 | 2010 | 1430 | 0.130 |
Why?
|
| Globus Pallidus | 3 | 2017 | 10 | 0.130 |
Why?
|
| Corpus Striatum | 3 | 2008 | 63 | 0.130 |
Why?
|
| Treatment Outcome | 7 | 2015 | 2943 | 0.130 |
Why?
|
| Female | 12 | 2017 | 13142 | 0.120 |
Why?
|
| Dopamine | 3 | 2007 | 77 | 0.120 |
Why?
|
| Nerve Growth Factors | 2 | 2010 | 33 | 0.120 |
Why?
|
| Animals | 8 | 2013 | 3271 | 0.120 |
Why?
|
| Substantia Nigra | 3 | 2007 | 102 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 2 | 2009 | 117 | 0.120 |
Why?
|
| Analysis of Variance | 3 | 2012 | 228 | 0.110 |
Why?
|
| Parkinsonian Disorders | 2 | 2009 | 170 | 0.110 |
Why?
|
| Feasibility Studies | 2 | 2014 | 210 | 0.110 |
Why?
|
| Adult | 7 | 2015 | 6959 | 0.110 |
Why?
|
| Movement Disorders | 1 | 2015 | 57 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 598 | 0.110 |
Why?
|
| Disease Models, Animal | 4 | 2013 | 526 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 578 | 0.100 |
Why?
|
| Electric Stimulation Therapy | 2 | 2010 | 39 | 0.100 |
Why?
|
| Colon | 1 | 2013 | 112 | 0.090 |
Why?
|
| Intraoperative Period | 1 | 2012 | 22 | 0.090 |
Why?
|
| alpha-Synuclein | 1 | 2013 | 103 | 0.090 |
Why?
|
| Skull | 1 | 2012 | 16 | 0.090 |
Why?
|
| Observer Variation | 1 | 2012 | 83 | 0.090 |
Why?
|
| Cell Count | 2 | 2009 | 72 | 0.090 |
Why?
|
| Microelectrodes | 2 | 2009 | 18 | 0.090 |
Why?
|
| Functional Laterality | 2 | 2010 | 54 | 0.090 |
Why?
|
| Radiography | 1 | 2012 | 521 | 0.080 |
Why?
|
| Alzheimer Disease | 2 | 2014 | 1414 | 0.080 |
Why?
|
| Subthalamic Nucleus | 2 | 2017 | 19 | 0.080 |
Why?
|
| Antiparkinson Agents | 2 | 2002 | 41 | 0.080 |
Why?
|
| CA3 Region, Hippocampal | 1 | 2009 | 4 | 0.080 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2009 | 6 | 0.080 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2009 | 8 | 0.080 |
Why?
|
| Cell Survival | 1 | 2009 | 99 | 0.080 |
Why?
|
| Pyramidal Cells | 1 | 2009 | 34 | 0.080 |
Why?
|
| Blepharospasm | 1 | 2009 | 1 | 0.070 |
Why?
|
| Torticollis | 1 | 2009 | 8 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 71 | 0.070 |
Why?
|
| Transgenes | 1 | 2008 | 10 | 0.070 |
Why?
|
| Medical Records | 1 | 2008 | 28 | 0.070 |
Why?
|
| Tyrosine 3-Monooxygenase | 4 | 2013 | 51 | 0.070 |
Why?
|
| Aged | 5 | 2015 | 7660 | 0.070 |
Why?
|
| Drinking | 1 | 2007 | 6 | 0.070 |
Why?
|
| Eating | 1 | 2007 | 47 | 0.070 |
Why?
|
| Autopsy | 1 | 2008 | 260 | 0.060 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2007 | 7 | 0.060 |
Why?
|
| MPTP Poisoning | 1 | 2007 | 13 | 0.060 |
Why?
|
| Neostriatum | 1 | 2007 | 13 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 314 | 0.060 |
Why?
|
| Inflammation | 1 | 2008 | 230 | 0.060 |
Why?
|
| Motor Activity | 3 | 2010 | 274 | 0.060 |
Why?
|
| Rats | 1 | 2007 | 622 | 0.060 |
Why?
|
| Combined Modality Therapy | 3 | 1997 | 294 | 0.060 |
Why?
|
| Cholinergic Fibers | 1 | 2005 | 8 | 0.060 |
Why?
|
| Prosencephalon | 1 | 2005 | 8 | 0.060 |
Why?
|
| Brain Tissue Transplantation | 2 | 1997 | 15 | 0.060 |
Why?
|
| Fetal Tissue Transplantation | 2 | 1997 | 22 | 0.060 |
Why?
|
| Adolescent | 1 | 2009 | 1884 | 0.050 |
Why?
|
| Young Adult | 1 | 2009 | 1657 | 0.050 |
Why?
|
| Phonation | 1 | 2003 | 4 | 0.050 |
Why?
|
| Speech Disorders | 1 | 2003 | 10 | 0.050 |
Why?
|
| Electric Stimulation | 1 | 2003 | 46 | 0.050 |
Why?
|
| Respiration | 1 | 2003 | 27 | 0.050 |
Why?
|
| Speech | 1 | 2003 | 21 | 0.050 |
Why?
|
| Aging | 2 | 2007 | 1180 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2013 | 804 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2014 | 75 | 0.040 |
Why?
|
| Registries | 2 | 1991 | 174 | 0.040 |
Why?
|
| Transplantation, Autologous | 2 | 1997 | 98 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2010 | 374 | 0.040 |
Why?
|
| Time Factors | 2 | 2013 | 1264 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 28 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2008 | 26 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2017 | 39 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 2014 | 917 | 0.030 |
Why?
|
| Macaca mulatta | 2 | 2007 | 56 | 0.030 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 2 | 2010 | 23 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 152 | 0.030 |
Why?
|
| Basal Nucleus of Meynert | 1 | 2014 | 7 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2013 | 5 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2013 | 10 | 0.030 |
Why?
|
| Vagus Nerve | 1 | 2013 | 14 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2013 | 9 | 0.030 |
Why?
|
| Permeability | 1 | 2013 | 94 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 202 | 0.020 |
Why?
|
| Adrenal Glands | 1 | 1993 | 10 | 0.020 |
Why?
|
| Thalamus | 1 | 1993 | 15 | 0.020 |
Why?
|
| Mesencephalon | 1 | 1993 | 21 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 115 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 363 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 547 | 0.020 |
Why?
|
| Chromogranins | 1 | 1991 | 3 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1991 | 10 | 0.020 |
Why?
|
| Epilepsies, Partial | 1 | 2010 | 11 | 0.020 |
Why?
|
| Mice | 1 | 2013 | 1240 | 0.020 |
Why?
|
| Dysarthria | 1 | 2009 | 2 | 0.020 |
Why?
|
| Dominance, Cerebral | 1 | 2009 | 14 | 0.020 |
Why?
|
| Memory Disorders | 1 | 2010 | 116 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 192 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2009 | 82 | 0.020 |
Why?
|
| Motor Skills | 1 | 2009 | 38 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2008 | 25 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 130 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2009 | 124 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2007 | 11 | 0.020 |
Why?
|
| Cytoprotection | 1 | 2006 | 9 | 0.020 |
Why?
|
| Nerve Regeneration | 1 | 2006 | 13 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2007 | 47 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 29 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1106 | 0.020 |
Why?
|
| Depression | 1 | 2010 | 383 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2006 | 54 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2006 | 242 | 0.010 |
Why?
|
| Histological Techniques | 1 | 2005 | 6 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2005 | 50 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2005 | 35 | 0.010 |
Why?
|
| Speech Articulation Tests | 1 | 2003 | 3 | 0.010 |
Why?
|
| Acoustics | 1 | 2003 | 12 | 0.010 |
Why?
|
| Task Performance and Analysis | 1 | 2003 | 44 | 0.010 |
Why?
|
| Lentivirus | 1 | 2002 | 7 | 0.010 |
Why?
|
| Haplorhini | 1 | 2002 | 8 | 0.010 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2002 | 16 | 0.010 |
Why?
|
| Dopamine Agents | 1 | 2002 | 11 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 53 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 69 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 369 | 0.010 |
Why?
|
| Cognition | 1 | 2005 | 1026 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1997 | 198 | 0.010 |
Why?
|
| Data Collection | 1 | 1991 | 83 | 0.010 |
Why?
|
| Chromogranin A | 1 | 1991 | 8 | 0.010 |
Why?
|
| Forms and Records Control | 1 | 1990 | 8 | 0.000 |
Why?
|
| Canada | 1 | 1990 | 42 | 0.000 |
Why?
|
| Levodopa | 1 | 1990 | 34 | 0.000 |
Why?
|
| Prognosis | 1 | 1991 | 730 | 0.000 |
Why?
|
| Chicago | 1 | 1990 | 847 | 0.000 |
Why?
|
| United States | 1 | 1990 | 1803 | 0.000 |
Why?
|